Chemokine responsive activated natural killer cells with secondary homing activation for verified targets
AssigneeImmunityBio, Inc.
InventorsNathan Schomer, Laurent Boissel, Hans Klingemann
Life of this patent
Estimating the term…
Abstract
Provided herein are modified NK-92 cells comprising a nucleic acid encoding C-C chemokine receptor type 7 (CCR7) operably linked to a promoter. Optionally, the cells further comprise a nucleic acid encoding C-C motif ligand 21 (CCL21), a nucleic acid encoding C-C motif ligand 19 (CCL19) or a combination thereof. Also provided are compositions and kits comprising the modified NK-92 cells. Provided are methods of making the modified cells and methods of treating cancer using the cells.
Claims7
A modified NK-92 cell comprising (i) a nucleic acid encoding C-C chemokine receptor type 7 (CCR7) operably linked to a promoter, and (ii) a nucleic acid encoding C-C motif ligand 21 (CCL21) operably linked to a promoter,
- wherein the promoter operably linked to CCL21 comprises one or more NFAT binding elements SEQ ID NO:4 and a minimal promoter SEQ ID NO:5, and has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to SEQ ID NO:6.
Dependencies are inferred from the claim text.